A phase I study to establish the safety and efficacy of retinal pigment epithelium micropulse laser in subjects with high-risk drusen secondary to age-related macular degeneration

Barcelona Macula Foundation
Institut de la Màcula i de la Retina

The crystal study: a 24-month, phase iiib, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven pro re nata dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (crvo)

Barcelona Macula Foundation
Institut de la Màcula i de la Retina

Més 70 centres clínics a tot el món

The brighter study: a 24-month, phase iiib, openlabel, randomized, active-controlled, threearm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven pro re nata dosing regimen with 0.5- mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (brvo)

Barcelona Macula Foundation
Institut de la Màcula i de la Retina
And 45 more clinical sites worldwide

Phase IV study to evaluate the efficacy of a vegf trap-eye in subjects with neovascular age-related macular degeneration (wamd), without optimal response to repeated monthly intravitreal injections of anti vegf-a therapy

Barcelona Macula Foundation
Institut de la Màcula i de la Retina
A further nine clinical sites in Spain to be decided

A phase II randomized, double-mask study to establish the safety and efficacy of high-dose oral omega 3 in subjects with geographic atrophy secondary to dry age-related macular degeneration

Barcelona Macula Foundation
Institut de la Màcula i de la Retina

A phase I study to establish the safety and tolerability of arc1905 (anti-c5 aptamer) in subjects with dry age-related macular degeneration

Institut de la Màcula i de la Retina
Barcelona Macula Foundation

A phase II, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous injections of e10030 (anti-pdgf pegylated aptamer) given in combination with lucentis® in subjects with neovascular age-related macular degeneration

Institut de la Màcula i de la Retina
Barcelona Macula Foundation

An open-label investigator research grant trial to establish the safety of intravitreous injections of e10030 (anti-pdgf pegylated aptamer) given in combination with lucentis® in subjects with neovascular age-related macular degeneration

Institut de la Màcula i de la Retina
Barcelona Macula Foundation